AR099872A1 - Formulaciones de progesterona - Google Patents
Formulaciones de progesteronaInfo
- Publication number
- AR099872A1 AR099872A1 ARP150100920A ARP150100920A AR099872A1 AR 099872 A1 AR099872 A1 AR 099872A1 AR P150100920 A ARP150100920 A AR P150100920A AR P150100920 A ARP150100920 A AR P150100920A AR 099872 A1 AR099872 A1 AR 099872A1
- Authority
- AR
- Argentina
- Prior art keywords
- progesterone
- subject
- need
- amount
- auc0
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461972068P | 2014-03-28 | 2014-03-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR099872A1 true AR099872A1 (es) | 2016-08-24 |
Family
ID=54196452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150100920A AR099872A1 (es) | 2014-03-28 | 2015-03-27 | Formulaciones de progesterona |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP3122364A4 (fr) |
JP (2) | JP2017509630A (fr) |
KR (1) | KR20160137597A (fr) |
AR (1) | AR099872A1 (fr) |
AU (1) | AU2015237243A1 (fr) |
CA (1) | CA2942568A1 (fr) |
IL (1) | IL247828A0 (fr) |
MX (1) | MX2016011706A (fr) |
RU (1) | RU2016136666A (fr) |
WO (1) | WO2015148952A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210386757A1 (en) * | 2018-10-17 | 2021-12-16 | Sarah S. Stadler | Methods of Treating Menopausal Symptoms Using Low Dose Progesterone |
CN112336699A (zh) * | 2019-08-09 | 2021-02-09 | 南京科宁检测科技有限公司 | 一种黄体酮阴道缓释软胶囊及其制备方法 |
US20220105107A1 (en) * | 2020-10-01 | 2022-04-07 | Michael Liguori | Bioidentical progesterone cream infused with nanoemulsified cbd |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US20020119198A1 (en) * | 2000-07-24 | 2002-08-29 | Ping Gao | Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs |
JP2005526083A (ja) * | 2002-03-14 | 2005-09-02 | ワトソン ファーマシューティカルズ, インコーポレイテッド | プロゲステロンの経口薬物送達システム |
US8663681B2 (en) * | 2005-05-26 | 2014-03-04 | Teva Women's Health, Inc. | Oral dosage forms comprising progesterone and methods of making and using the same |
US20110312927A1 (en) * | 2010-06-18 | 2011-12-22 | Satish Kumar Nachaegari | Progesterone Containing Oral Dosage Forms and Related Methods |
US20110312928A1 (en) * | 2010-06-18 | 2011-12-22 | Lipocine Inc. | Progesterone Containing Oral Dosage Forms and Related Methods |
US9301920B2 (en) * | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) * | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US20130338122A1 (en) * | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
-
2015
- 2015-03-27 MX MX2016011706A patent/MX2016011706A/es unknown
- 2015-03-27 KR KR1020167029519A patent/KR20160137597A/ko unknown
- 2015-03-27 RU RU2016136666A patent/RU2016136666A/ru not_active Application Discontinuation
- 2015-03-27 WO PCT/US2015/023041 patent/WO2015148952A1/fr active Application Filing
- 2015-03-27 AU AU2015237243A patent/AU2015237243A1/en not_active Abandoned
- 2015-03-27 JP JP2016557059A patent/JP2017509630A/ja active Pending
- 2015-03-27 AR ARP150100920A patent/AR099872A1/es unknown
- 2015-03-27 EP EP15768772.4A patent/EP3122364A4/fr not_active Withdrawn
- 2015-03-27 CA CA2942568A patent/CA2942568A1/fr not_active Abandoned
-
2016
- 2016-09-14 IL IL247828A patent/IL247828A0/en unknown
-
2019
- 2019-07-05 JP JP2019126362A patent/JP2019206540A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3122364A4 (fr) | 2017-10-25 |
RU2016136666A3 (fr) | 2018-11-07 |
KR20160137597A (ko) | 2016-11-30 |
WO2015148952A1 (fr) | 2015-10-01 |
JP2019206540A (ja) | 2019-12-05 |
RU2016136666A (ru) | 2018-05-03 |
CA2942568A1 (fr) | 2015-10-01 |
MX2016011706A (es) | 2017-05-01 |
EP3122364A1 (fr) | 2017-02-01 |
JP2017509630A (ja) | 2017-04-06 |
IL247828A0 (en) | 2016-11-30 |
AU2015237243A1 (en) | 2016-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017012706A2 (pt) | formulações de sunitinibe e métodos para uso destas no tratamento de transtornos oculares | |
BR112012033077B8 (pt) | Composição farmacêutica para administração intravenosa, uso de uma composição farmacêutica, e, kit | |
CL2019000248A1 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
CO2019000938A2 (es) | Moduladores nmda espiro-lactam y métodos de uso de los mismos | |
CR20140086A (es) | Tratamientos de combinación para hepatitis c | |
CO2019000944A2 (es) | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos | |
CL2019000247A1 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos. | |
AR084816A1 (es) | Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer | |
AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
CL2019003533A1 (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
PE20170773A1 (es) | Formulaciones farmaceuticas, procesos para la preparacion, y metodos de uso | |
CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
AR099872A1 (es) | Formulaciones de progesterona | |
CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. | |
BR112012030654A2 (pt) | formas de dosagem oral de bendamustina | |
CL2016002318A1 (es) | Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits. | |
CL2020000601A1 (es) | Composición farmacéutica. | |
CL2020000019A1 (es) | Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso. | |
MX2017005163A (es) | Composiciones de liberación prolongada de onapristona y métodos. | |
AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
AR086491A1 (es) | Composicion farmaceutica que comprende fexofenadina | |
CL2021000627A1 (es) | Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular | |
BR112018008835A8 (pt) | composição farmacêutica oral, composição farmacêutica de liberação pulsátil oral, método para tratar uma condição de doença que requer terapia com fumarato de dimetila e método para tratar esclerose múltipla |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |